Skip to main content
Clinical Trials/NCT03476811
NCT03476811
Completed
Phase 2

Postoperative subQ Pain Control for Spinal Fusion Surgery

University of Arizona1 site in 1 country11 target enrollmentFebruary 9, 2018

Overview

Phase
Phase 2
Intervention
0.25% Marcaine at 2ml/hr and pain medications
Conditions
Spine Fusion
Sponsor
University of Arizona
Enrollment
11
Locations
1
Primary Endpoint
Pain control
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Post-operative pain following lumbar spine fusion is frequently difficult to manage and can lead to increased doses of opiate pain medications to control pain. In this study, the use of subcutaneous local anesthesia will be studied to determine its efficacy at reducing post-operative pain following spinal fusion surgery.

Detailed Description

For patients randomized to the experimental or to the placebo groups, two subcutaneous catheters will be tunneled under the skin with large hollow-bore needles along the entire length of the incision on either side prior to closure. These catheters will deliver study drug (0.25% Marcaine) directly into the incision. They will be affixed to the skin with steri-strips. The catheters will then be attached to a drug delivery pump at 2mL/hour and will be removed prior to discharge.

Registry
clinicaltrials.gov
Start Date
February 9, 2018
End Date
June 30, 2021
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Robert Bina

Neurosurgery Resident

University of Arizona

Eligibility Criteria

Inclusion Criteria

  • Patient 18 years of age or greater
  • Surgery to be done at Banner University Medical Center-Tucson
  • Elective Surgeries only
  • Lower Thoracic or Lumbar fusions only - Posterior Approach
  • Postero or Posterolateral Instrumented Fusions with or without Interbody graft
  • Transforaminal Interbody Fusions
  • Must be able to cooperate in the daily VAS assessment

Exclusion Criteria

  • Patients under 18 years of age
  • Prisoners
  • Pregnant women
  • Hypersensitivity to infusion medication
  • Deformity Correction cases requiring osteotomies
  • Surgical fusion in acute phase for traumatic injury
  • Anterior Lumbar Interbody Fusion, Direct Lateral Interbody Fusion procedures

Arms & Interventions

Marciano Group

Subcutaneous pain control with OnQ pump (0.25% Marcaine at 2ml/hr) and pain medications.

Intervention: 0.25% Marcaine at 2ml/hr and pain medications

Placebo Group

OnQ pump with placebo (normal saline at 2ml/hr) and pain medications.

Intervention: Placement of OnQ Drug pump

Outcomes

Primary Outcomes

Pain control

Time Frame: From post operative day 1 until patient discharge or 30 days, whichever comes first

A daily Visual Analog Score Pain scale (1-10) for pain severity, (1 least pain, 10 most pain) will be assessed and recorded daily by a blinded assessor.

Secondary Outcomes

  • Time to discharge(from the day of hospital admission to the day of hospital discharge or 45 days, whichever comes first.)
  • Total Milligrams of IV pain medication(from the first post-operative dose of IV pain medication until the last dose prior to discharge from the hospital or 45 days, whichever comes first)
  • Total Doses of IV pain medication(from the first post-operative dose of IV pain medication until the last dose prior to discharge from the hospital or 45 days, whichever comes first)
  • Total Milligrams of oral pain medication(from the first post-operative dose of oral pain medication until the last dose prior to discharge from the hospital or 45 days, whichever comes first)
  • Total Doses of oral pain medication(from the first post-operative dose of oral pain medication until the last dose prior to discharge from the hospital or 45 days, whichever comes first)

Study Sites (1)

Loading locations...

Similar Trials